Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis.

Rev Cardiovasc Med · 2025 · PMC11951278 · PMID 40160567

Europe PMC DOI

hedged sentence

0.2060

closest p · 4.1× alpha

0.2060

boldest claim

The sentences

did not reach statistical significancep = 0.206not close (p > 0.1)

Peak VO 2 , a crucial indicator of aerobic and cardiovascular capacity, exhibited a more favorable trend in the SGLT2i group, which showed a slight improvement of 0.1 [–1.4 to 0.8] compared to a decline in the control group of –1.3 [–2.3 to –0.2], though this difference did not reach statistical significance ( p = 0.206).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.